الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 210 |  |  |
| | | from | 210 | | |
المستخلص
The present work was designed to study of the effects of glibenclamide, rosiglitazone, rilmenidine and bromocriptine on fasting plasma levels of glucose, insulin, lipids (cholestrol TG,HDL and LDL) and pancreatic ultrastructure changes in STZtreated
rats. The experimental investigations were conducted on intact animals as well as on isolated preparations.
The rats were divided into; Normal control, Citrate buffer and diabetic groups for eight weeks. The diabetic groups subdivided into a- Control diabetic group that received STZ, a
single IV injection into the rat tail vein of a low dose
(35mg/kg) dissolved into 1 ml of 0.05 M citrate buffer. This
group received 1 ml distilled water orally equal to volume
used as a vehicle for all drugs and b- Treated diabetic groups,
which received STZ, a single IV injection of a low dose
(35mg/kg) then recieved glibenclamide, rosiglitazone, rilmenidine
and bromocriptine (5, 0.6, 1, 0.05 mg/kg respectively) for
8 weeks.
The in-vivo study showed that:
In the present work induction of diabetes chemically by
streptozotocin (35mg/kg i.v. single dose) resulted in significant
elevation in fasting plasma glucose level, significant reduction
in plasma insulin level and produced significant elevations in
fasting plasma levels of total cholesterol, triglycerides and
LDL with a significant decrease into fasting plasma HDL level.
Glibenclamide administration produced a significant decrease
in fasting plasma glucose level and a significant elevation
in fasting plasma insulin level. It also produced significant
decrease into fasting plasma total cholesterol level, a significant
decrease in fasting plasma LDL level, a significant elevation
of fasting plasma level of HDL level and insignificant
changes on fasting plasma triglycerides level.